Search
gamma-Butyrolactone
go.drugbank.com/drugs/DB04699ExperimentalIllicitIt is also used as a pharmacological agent and solvent. … One of the furans with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate.
Categories: Compounds used in a research, industrial, or household settingLawsone
go.drugbank.com/drugs/DB04744ExperimentalCategories: Compounds used in a research, industrial, or household settingSuramin
go.drugbank.com/drugs/DB04786InvestigationalA polyanionic compound with an unknown mechanism of action.
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnThis decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigational[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.
Lucanthone
go.drugbank.com/drugs/DB04967InvestigationalIt is currently being tested as a radiation sensitizer.
Canfosfamide
go.drugbank.com/drugs/DB04972InvestigationalCanfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalBelinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexMitoquinone
go.drugbank.com/drugs/DB05063Investigational-- where they accumulate up to a thousand fold. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.
Lobeline
go.drugbank.com/drugs/DB05137InvestigationalIt has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]